Telebrix 38
Telebrix 38 Uses, Dosage, Side Effects, Food Interaction and all others data.
Ioxitalamate is an ionic iodinated contrast medium. It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg. Telebrix 38 in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995. Until the last review in 2015, this drug is still available in the market.
Ioxitalamate presents a very large osmolality which is related to the presence of renal toxicity, vasodilatation, bradycardia and pulmonary hypertension. This large osmolality allows ioxitalamate to move slowly in the bowel allowing for analysis for later follow excretion in the feces.
| Trade Name | Telebrix 38 |
| Generic | Ioxitalamic acid |
| Ioxitalamic acid Other Names | Acide ioxitalamique, Acido ioxitalamico, Acidum ioxitalamicum, Ioxitalamic acid |
| Type | |
| Formula | C12H11I3N2O5 |
| Weight | Average: 643.942 Monoisotopic: 643.78021 |
| Protein binding | Iodinated monomeric contrast agents are rarely bound to plasma proteins and when they bind, usually the association is very weak. When bound, it only represents from 0 to 27% of the ioxitalamate administered dose. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Telebrix 38 is a contrast agent used for CT scans of the abdomen and pelvis.
Ioxitalamate in both of its available forms is indicated for exploration of the digestive tract by tomodensitometry or by regular gastroduodenal radiography. Its use is restrained to the cases in which the administration of barium sulfate is not recommended or contraindicated. The intravascular administration of ioxitalamate is contraindicated as it may present significant side effects.
How Telebrix 38 works
Ioxitalamate acts as a bowel opacifier which facilitates the interpretation of the anatomy and differentiation of bowel loops from soft tissue masses.
Toxicity
Ioxitalamate is reported to induce acute kidney injury. Preclinical studies showed that it does not present a teratogenic potential as well as a lack of effect on fertility. Ioxitalamate overdose may increase the risk of nephropathy and cardiovascular disorders.
Food Interaction
No interactions found.Volume of Distribution
The volume of distribution of ioxitalamate is 194 ml/kg.
Elimination Route
When administered ioxitalamate is not absorbed in the GI tract. In the case of presence of an intestinal perforation, ioxitalamate is completely absorbed. When administered intravascularly, ioxitalamate is rapidly distributed in the interstitial space and intravascular compartment.
Half Life
The elimination half-life of ioxitalamate is 1.1 hours.[T56]
Clearance
The total clearance rate of ioxitalamate is 120 ml/min.
Elimination Route
As ioxitalamate is not absorbed in the normal intestine, the elimination route of this compound is entirely performed by the feces. When absorbed due to the presence of an intestinal perforation, ioxitalamate presents a rapid renal elimination. when ioxitalamate is administered intravascularly, it is eliminated unchanged mainly via renal excretion through glomerular filtration without reabsorption or tubular secretion. In the cases of renal failure, the elimination is mainly performed in the biliary, salivary, sudoral and colic route.
Innovators Monograph
You find simplified version here Telebrix 38
